Background: Epidermal growth factor-containing fibulin-like extracellular matrix protein 2 (EFEMP2), also known as fibulin-4, MBP1 and UPH1, is an extracellular matrix protein associated with a variety of tumors. The purpose of this study was to investigate the prognostic value and the function of EFEMP2 in lung cancer. Methods: The mRNA and protein expression of EFEMP2 in lung normal and cancer tissues, lung cancer cell lines (A549, H460, H1299 and H1650) and normal epithelial cell line BEAS-2B were evaluated by immunohistochemistry, RT-qPCR and Western blotting. The Public databases (Oncomine and Kaplan-Meier plotter) were used to investigate the prognostic value of EFEMP2 in lung cancer. RNA interference (RNAi) and overexpression transfection were performed to detect the effects of EFEMP2 up-or down-regulation on lung normal and cancer cell proliferation, invasion and metastasis in vitro and in vivo. Results: EFEMP2 was lowly expressed in lung cancer tissues and cells, and its low expression was associated with malignant phenotype and poor prognosis of lung cancer. The same conclusion had been drawn from the Public databases. EFEMP2 overexpression significantly inhibited the invasion of lung cancer cells, hampered the process of EMT, and decreased the expression and activity of MMP2 and MMP9, while EFEMP2 knockdown remarkably enhanced the invasion of lung cancer cells, promoted EMT, and increased the expression and activity of MMP2 and MMP9. Conclusion: The low expression of EFEMP2 was detected in lung cancer and was positively correlated with the poor prognosis of patients. EFEMP2 was a tumor suppressor gene that inhibited the progress of lung cancer, which suggested a new research objective for the future studies.
Introduction
Lung cancer occurs in the bronchial mucosal epithelium, and the incidence of lung cancer has been significantly increased in the last 50 years. In the industrial developed countries of Europe and America and some big industrial cities in China, the incidence of lung cancer has ranked first among male malignant tumors, and the incidence of lung cancer in women has also increased rapidly, accounting for the second or third place of women common malignant tumors. There are about 1.8 million new cases of lung cancer worldwide each year, with more than 1.6 million deaths. Lung cancer has become a major disease endangering life and health. 1 The early diagnosis of lung cancer is difficult. About 85% of the patients are in the advanced stage of diagnosis, and the effect of surgical treatment is not ideal. The 5-year survival rate is only 16%, which is in sharp contrast to the high survival rate of 90%, 65% and nearly 100% for breast cancer, colon cancer and prostate cancer, respectively. 2 Surgical treatment has been recognized as the first choice for the treatment of lung cancer, but most of the patients missed the opportunity of radical surgery, and the invasion, metastasis and poor prognosis of advanced tumors are still difficult to solve. Gene therapy and targeted therapy have been paid more and more attention as a new generation model of tumor therapy. Molecular targeted drugs can specifically select carcinogenic sites and kill tumor cells without affecting the normal tissue cells around them. Therefore, molecular targeted therapy is also known as "biological missiles". Compared with traditional chemotherapeutic drugs, molecular targeted drugs have the advantages of strong specificity, obvious curative effect and less side effects. However, no specific markers have been found in the treatment of lung cancer, and there is a lack of understanding of the molecular mechanism of invasion and metastasis. 3 therefore, clarifying the mechanism of lung cancer invasion and metastasis and finding effective targeting drugs to inhibit invasion and metastasis is essential to fully improve the prognosis of patients. Epidermal growth factor-containing fibulin-like extracellular matrix protein 2 (EFEMP2, also known as fibulin-4, MBP1 and UPH1), is a member of fibulin glycoprotein family. [4] [5] [6] Fibulins are a family of seven extracellular matrix proteins characterized by a tandem array of calcium-binding (cb) epidermal growth factor (EGF)-like modules and a fibulin-type C-terminal domain. [7] [8] [9] EFEMP2 is a 443 amino acid secretory protein and contains of a N-terminal modified cbEGF module, five consecutive cbEGF modules and the FC domain. 4 EFEMP2 is often found in tissues and organs that are rich in elastic fibers, including the blood vessels, heart valves, lung and skin. 7, 10 This gene is necessary for elastic fiber formation and connective tissue development, and plays an important role in stabilizing the extracellular matrix structure. 11, 12 Defects of EFEMP2 in patients have been linked to many diseases, such as autosomal recessive cutis laxa syndrome, aneurysms and tortuosity of the large arteries, developmental emphysema, diaphragmatic and inguinal hernia, joint laxity and cancer. [13] [14] [15] The role of EFEMP2 in tumorigenesis has not yet been fully elucidated, both carcinogenic and anti-carcinogenic effects have been reported. High expression of EFEMP2 was associated with tumor progress and poor prognosis in cervical carcinoma, 16 ovarian carcinoma, 17 glioblastoma 18 and osteosarcoma. 19 However, in human endometrial carcinoma, EFEMP2 demonstrated inhibitory effects in tumor invasion and metastasis. 20 These ostensibly contradictory findings in different cancers may reflect "context-specific" roles of EFEMP2. Little is known about the direct molecular function of EFEMP2 in cancer progressions. Till now, the function of EFEMP2 in lung cancer has not been explored, so the purpose of this study is to detect the expression of EFEMP2 in lung cancer and its relationship with the progress of lung cancer. 
Materials and Methods

Tumor Tissues Samples
Evaluation of IHC and ICC Staining
To evaluate the staining results of IHC and ICC, a semiquantitative scoring system was used in this study. 21 The staining score was calculated according to the staining strength and the proportion of positive stained cells in tissue sections or cell coverslips. The staining strength was scored from 0 to 3: no staining scored 0, weak staining scored 1, medium staining scored 2, and strong staining scored 3. The proportion of positive stained cells was scored from 0 to 4: 0% positive stained cells scored 0, 1%-25% positive stained cells scored 1, 26%-50% positive stained cells scored 2, 51%-75% positive stained cells scored 3, and 76%-100% positive stained cells scored 4. The sum of staining strength and positive cell proportion score was the total staining score (0 to 7). To facilitate statistical analysis, the total staining score was transformed into sum indexes (-), (+), (++), and (+++), corresponding to score 0, (1-3), (4) (5) , and (6-7), respectively. The sum indexes (-) and (+) were considered low expression and (++) and (+++) were considered high expression. Three pathologists graded each section and coverslip independently; in the case of differences in scores, an agreement was reached through the discussion.
Analysis of the Oncomine and Kaplan-Meier Plotter Public Databases
In this study, Oncomine array datasets (www.oncomine. org) were utilized to compare the expression of EFEMP2 between clinical lung cancer specimens and normal controls. The detailed information of standardization technology and statistical calculation is provided on Oncomine platform. The prognostic value of EFEMP2 in patients with lung cancer was investigated in Kaplan-Meier Plotter public databases (http://kmplot.com/analysis/). The Kaplan-Meier Plotter estimates the survival function from life-time data and visualize the association between the biomarker and the survival, in which the patients are divided into groups based on the parameters. Log rank test is used to compare the survival curves of two or more groups. Hazard ratios with 95% confidence interval and logrank P value are calculated and displayed.
Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR)
TRIZol reagent (TaKaRa Biotechnology, China) was used to get total RNA, after quantification and dilution to 500 ng/ µL, of which 2 µL was reverse transcribed to complementary DNA (cDNA) by PrimeScript TM RT reagent Kit (TaKaRa). Then RT-qPCR was performed using TB Green™ Premix Ex Taq™ II kit (TaKaRa) by LightCycler 480 System (Roche Diagnostics). A 20-μL reaction system, including 10 µL TB Green Premix Ex Taq II (2× Tli RNaseH Plus), 0.8 µL forward primer (10 µM), 0.8 µL reverse primer (10 µM), 2 µL DNA template (< 100 ng), and 6.4 µL DNAse/RNAse-free water (Sigma-Aldrich), was added into each well of a 96-well plate, and there were three technical replicas. According to the instructions of the manufacturer, the standard two-step PCR reaction program is run, and the quantitative standard curve is generated. Relative quantitative gene expression levels were analyzed by the convenient 2(-Delta Delta C(T)) method. 22 The specific forward or reverse primers were designed and synthesized by Takara Biotechnology Co., Ltd, the sequences of them were given in Table 1 . 
Western Blotting
Cell Growth Curve Assay
Cell growth curve is not only an important index to determine the vitality of cells, but also one of the basic parameters of the biological characteristics of cultured cells. So it can accurately describe the dynamic changes of the number of cells during the whole growth process. The cells with good growth and close to confluence were digested with trypsin and counted after being made into cell suspension with new culture medium. According to the results of the cell count, the cells were inoculated into 24-well plates (1 × 10 4 cells/well) and cultured in 37°C and 5% CO 2 incubator. From the next day, three wells of cells were taken every 24 h and counted respectively, and their average values were taken for continuous 7 days in a row. According to the results of cell count, the growth curve was drawn with number of living cells as longitudinal coordinate and time as transverse coordinate.
Plate Clone Formation Assay
The cell plate clone formation assay reflects two important traits of cells: population dependence and proliferation ability. In each group, the logarithmic cells were collected and fully blown into single cell suspension to disperse the cells completely. And then the suspension was gradually 
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OncoTargets and Therapy 2020:13 diluted to ensure that only 500 cells were inoculated into 35mm petri dish and cultured at 37°C, 5% CO 2 and saturated humidity for 2 weeks. When the culture terminated, the clones were visible to the naked eye. Discard the culture medium from the dishes and carefully rinse twice with PBS. The cell clones were fixed by 4% paraformaldehyde for 30 mins and stained by GIMSA staining solution for 10 mins. The number of clones greater than 50 cells was counted under a microscope (low-fold mirror), and the average of three dishes was recorded.
In vitro Cell Invasion and Migration Assay
Transwell chamber, also named as Boyden chamber, consists of two compartments separated by a microporous membrane with a pore size of 8 µm, is commonly used and highly accessible method for examining cell migration and invasion in vitro. The transwell cell migration assay can be used to determine the migration ability of cells toward a chemo-attractant. The transwell cell invasion assay measures both cell chemotaxis and the invasion of cells through ECM (extracellular matrix), which commonly occurred in the process of tumor metastasis. For cell migration assay, add 150 μL of cell solution (1×10 6 cells/mL) on top of the filter membrane in the 24-well transwell insert and 600 μL of serum-free conditioned medium of NIH3T3 cells as the chemotactic factor into the bottom of the lower chamber. After culture for 12 h at 37°C with 5% CO 2 , pick up the transwell insert from the plate and carefully remove the remaining cells that had not migrated across the membrane. Next, put the transwell insert into 4% paraformaldehyde to fix the migrated cells for 30 min and then stain them by Hematoxylin and Eosin staining kit (Beyotime Biotechnology, China). Finally, under an inverted microscope set at 200×magnification (OLYMPUS, BX63F, Japan), the number of stained cells migrated across the membrane to the other side were enumerated. For cell invasion assay, Matrigel (BD BioCoat), the ECM material, was thawed and liquefied on ice, and then diluted by serum-free medium at a ratio of 1:5, of which 50 μL is added on the top of the membrane in the transwell insert and solidified in a 37°C incubator for 30 min to form a thin gel layer, simulating the structure and physical properties of ECM. The other steps were the same as the cell migration assay, including the number of cells added on top of the Matrigel coating in the upper chamber and the amount of chemokines added to the lower chamber, as well as fixing, staining and counting methods, but the culture time was 24 h instead of 12 h.
Xenograft Tumor Model in vivo
Female BALB/C/nu/nu mice, 4-6 weeks old and weighed 18-22 g, were purchased from the National Rodent Experimental Animal Seed Center. They were randomly divided into up-regulation group, down-regulation group and corresponding negative control group (n = 5/group), and maintained in a specific pathogen free (SPF) environment with 20-26°C temperature and 40-60% humidity. Then, 0.3 mL targeted cell suspension (1 × 10 7 cells) was inoculated subcutaneously on the back and neck of the nude mice. After inoculation, the nude mice were raised in SPF environment for 2months. In the meantime, the professional was responsible for observing and recording tumorigenesis and overall health status of all nude mice. After 8 weeks, all nude mice were sacrificed by carbon dioxide (CO 2 ) euthanasia, and the subcutaneous tumors of each group were measured and dissected. 
Matrix Metalloproteinase (MMP) Zymography Assay
The activities of MMP2 and MMP9 were monitored using the matrix metalloproteinase zymography assay. Zymegraphy assay is a widely used method for detecting protease based on SDS-PAGE electrophoresis and reversed-phase gel staining. SDS-PAGE gel with collagenase substrate was prepared. The sample containing protease was electrolyzed in the gel. After electrophoresis, the gel was incubated with enzyme reaction buffer, and then stained and decolorized. The protease degraded the substrate protein in the gel, thus indicating the position and activity of MMP-2 and MMP-9 at the same time.
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 24.0. Measurement data are expressed as "mean ± SE" and analyzed using two independent sample two-tailed t-test (two groups) and one-way ANOVA (three and more groups, between groups with SNK or Dunnett-t test). However, numeration data were analyzed by χ 2 test or Fisher exact test. P < 0.05 (two-sided) was considered statistically significant.
Results
Expression of EFEMP2 in Normal Lung Tissue and Non-Small Cell Lung Cancer (NSCLC)
The results of IHC showed that the expression of EFEMP2 in normal lung tissue ( Figure 1A and B) was significantly higher than that of NSCLC ( Figure 1C-F) , and the staining was mainly focused on the cell membrane and cytoplasm. The percentage of EFEMP2 high-expression in normal lung tissue was 80.9% (55/68), which was significantly higher than that of NSCLC (14.4%) (50/347), see Table 2 .
Compared with poorly differentiated squamous cell carcinoma and adenocarcinoma ( Figure 1D and F), EFEMP2 was highly expressed in well-differentiated squamous cell carcinoma and adenocarcinoma ( Figure 1C and E).
Relationship Between the Expression of EFEMP2 and Clinicopathological Features of NSCLC Patients
The age of the NSCLC patients was from 30 to 86 years, with an average of 60 years old. There was no significant difference in the high expression rate of EFEMP2 between patients aged ≤ 60 years and > 60 years old with NSCLC (P > 0.05). Similarly, there was also no significant difference between female and male patients (P > 0.05). The expression level of EFEMP2 was not correlated with NSCLC histologic types, such as squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma (P > 0.05), but related to histological grade of squamous cell carcinoma, pathological subtype of adenocarcinoma, TNM clinical stage and lymph node metastasis (P < 0.05). The expression of EFEMP2 in welldifferentiated squamous cell carcinoma (I grade) was significantly higher than that in poorly differentiated squamous cell carcinoma (III grade). EFEMP2 showed significantly higher expression in lepidic adenocarcinomas (well-differentiated) than in solid and micropapillary adenocarcinomas (poorly differentiated) (P < 0.05). The high expression of EFEMP2 was negatively correlated with late clinical stage, low histological grade and positive lymph node metastasis in NSCLC patients, as shown in Table 3 .
Analysis of the Public Databases
Based on the analysis of Oncomine datasets, we found that in Bhattacharjee Lung Dataset, EFEMP2 mRNA expression in normal lung (17) (20), and 8.097 times higher than that in Small Cell Lung Carcinoma (6) (P < 0.05), as shown in Figure 1G and Table 4 . There were similar conclusions came from Selamat Lungo, Hou Lung, Landi Lung, Su Lung, Stearman Lung and Okayama Lung Oncomine datasets, which revealed that the mRNA expression of EFEMP2 was significantly reduced in lung carcinomas ( Table 4) . The relationship between the expression of EFEMP2 and the prognosis of patients with lung cancer was analyzed by public database KaplanMeier plotter. The patients were divided into two groups as having higher or lower expression of EFEMP2. Bonferroni multiple testing correction was applied when generating the P value. Survival curve was drawn with survival time as abscissa and survival probability as ordinate. The median survival time (survival probability was 0.5) in over expression group was much longer than that in lower expression group, and logrank P < 0.05 indicated that the good prognostic effect of the over expression EFEMP2 was highly significant. In one word, the prognosis of patients with high expression of EFEMP2 was significantly better than that with low expression of EFEMP2 (HR=0.77 (0.68-0.88), logrank P=5.7e-05). The low expression of EFEMP2 indicated poor prognosis in lung cancer patients ( Figure 1H ).
Expression of EFEMP2 in Normal Lung Epithelial Cells and 4 Lung Cancer Cell Lines
The results of Western blotting ( Figure 2A ) and RT-qPCR ( Figure 2B ) showed that the expression of EFEMP2 in 4 lung cancer cell lines (A549, H460, H1299 and H1650) was significantly lower than that in normal lung epithelial cell line BEAS-2B, at both mRNA and protein levels. We could get the same result from ICC ( Figure 2C ), and the staining was also focused on the cell membrane and cytoplasm, which was consistent with the IHC results of lung cancer tissue. The downward trend of EFEMP2 expression from normal lung to lung cancer in both tissues and cells suggested that the downregulation of EFEMP2 expression was closely related to the malignant phenotype of lung cancer cells.
Verification of Lentiviral Transfer Efficiency for EFEMP2 Knockdown and Overexpression
Based on the fact that EFEMP2 was highly expressed in normal lung epithelial cells and lowly expressed in lung cancer cells, we increased EFEMP2 expression in lung cancer cell lines H1299 and H1650 and decreased EFEMP2 expression in normal lung epithelial cell line BEAS-2B, in order to detect the function of EFEMP2 in proliferation, migration, invasion and metastasis of lung cancer cells in vivo and in vitro. For RNAi experiment, after 72 h of normal lung epithelial cell transfection, the rate of GFP positive cells under fluorescence microscope was more than 80%, which meant that the lentiviral transfer efficiency was higher ( Figure 3A and B) . Next, by RTqPCR ( Figure 3C ) and Western blotting ( Figure 3D ), we confirmed that the expression of EFEMP2 was remarkably down-regulated in BEAS-2B cells transfected with EFEMP2 shRNA, and there was no significant difference between the negative control shRNA transfected cells and the uninfected cells. For overexpression experiment, we also affirmed the successful and effective transfection in the lung cancer cell lines H1299 and H1650, with more than 80% GFP positive cells ( Figure 4A and B) and upregulation of EFEMP2 expression in EFEMP2 cDNA transfected cells at mRNA ( Figure 4C and E) and protein ( Figure 4D and F) levels. Notes: *There was no significant difference in the high expression rate of EFEMP2 among different NSCLC pathological types, such as squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma (P > 0.05). **There was a significant difference among I-III histological grade of squamous cell carcinoma, with the increase of the histological grade, the expression of EFEMP2 was decreased (P < 0.05). ***There was a significant difference among pathological subtype of adenocarcinoma, the expression of EFEMP2 in lepidic adenocarcinomas (well-differentiated) was significantly higher than that in other type of adenocarcinomas (P < 0.05).
Effects of EFEMP2 Up-or Down-Regulation on Lung Normal and Cancer Cell Migration and Invasive Activities in vitro
We evaluated the effects of EFEMP2 up-or downregulation on lung normal and cancer cell migration and invasion activity by cell migration and invasion assay using Transwell chambers. By comparing the average number of cells migrated through the PVPF membrane or invaded through the Matrigel among different groups, cell migration and invasion activity could be determined. In the cell migration assay ( Figure 5A ), when EFEMP2 expression was down-regulated, more cells migrated through the PVPF membrane in the EFEMP2 shRNA transfected group than in the control group, in contrast, when EFEMP2 expression was up-regulated, fewer cells migrated through the PVPF membrane in the EFEMP2 cDNA transfected group than in the control group. Thus, EFEMP2 down-regulation increased the migration capacity of normal lung epithelial cells, whereas EFEMP2 upregulation inhibited the migration capacity of lung cancer cells. Meanwhile, in the cell invasion assay ( Figure 5B ), when EFEMP2 expression was down-regulated, the average number of EFEMP2 shRNA-transfected cells that invaded through the Matrigel were considerably higher than that of the negative control cells, on the contrary, when EFEMP2 expression was up-regulated, the average number of EFEMP2 cDNA transfected cells that invaded through the Matrigel were significantly less than that of the negative control cells. Therefore, EFEMP2 downregulation increased the invasive capacity of normal lung epithelial cells, while EFEMP2 up-regulation inhibited the invasive capacity of lung cancer cells. In conclusion, EFEMP2 down-regulation promoted the migration and invasion ability of normal lung cells, while EFEMP2 upregulation inhibited the migration and invasion ability of lung cancer cells.
Effects of EFEMP2 Up-or Down-Regulation on Lung Normal and Cancer Cell Proliferation and Clonogenicity
The growth curves reflected the ability of cell growth and proliferation, and the plate clone formation assay reflected cell population dependence and clone formation potential. These two experiments were carried out to detect the effects of EFEMP2 up-or down-regulation on lung normal and cancer cell proliferation and clonogenicity. After RNAi experiment, growth curves showed that EFEMP2 shRNAtransfected cells grew faster and had a better proliferative ability than the negative control cells ( Figure 6A ). At the same time, the results of the plate clone formation assay showed that the average number of colonies formed by EFEMP2 shRNA-transfected cells was considerably higher than that formed by negative control cells ( Figure 6B ). In summary, EFEMP2 down-regulation distinctly promoted the proliferation and clonogenicity of normal lung epithelial cells. After overexpression experiment, compared with the negative control cells, EFEMP2 cDNA-transfected cells grew slowly ( Figure 6C ) and formed fewer clones ( Figure 6D ), which meant that EFEMP2 overexpression significantly inhibited the proliferation and clonogenicity of lung cancer cells. 
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OncoTargets and Therapy 2020:13 The colony numbers were markedly downregulated in EFEMP2 cDNA transfected H1299 and H1650 cells, compared to negative control groups. There was no significant difference between the negative control cDNA transfected cells and the uninfected cells. EFEMP2 knockdown evidently promoted normal lung cell proliferation and clonogenicity, meanwhile, EFEMP2 overexpression distinctly inhibited lung cancer cell proliferation and clonogenicity. *P < 0.05.
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OncoTargets and Therapy 2020:13 shRNA-transfected BEAS-2B cells were larger than that formed by the negative control cells, in contrast, the average subcutaneous tumor size in the EFENP2 cDNA transfected group was significantly smaller than that in the negative control group. EFEMP2 knockdown could promote tumor formation and growth in the nude mice, whereas EFEMP2 up-regulation could inhibit tumor growth in vivo. *P<0.05.
whereas EFEMP2 up-regulation could inhibit tumor growth in vivo.
Effects of EFEMP2 Up-or Down-Regulation on the EMT-Related Genes and Matrix Metalloproteinases (MMPs)
EMT is a special biological process, in which epithelial cells would lose cell polarity and epithelial phenotype and transform into mesenchymal cells with the phenotype of high migration and invasion and the ability of degrading the extracellular matrix (ECM). EMT plays an important role in embryonic development, chronic inflammation, tissue reconstruction, fibrotic diseases and cancer metastasis. 23, 24 From our present experiments, we found that EFEMP2 up-or down-regulation could affect the proliferation and invasion capacity of lung cancer cells in vitro and in vivo; therefore, we doubted whether EFEMP2 up-or down-regulation would affect the EMT related genes and MMPs. By Western blotting ( Figure 8A ), we found that at the protein level, in the EFEMP2 shRNA-transfected BEAS-2B cells, EFEMP2 down-regulation significantly decreased the expression of the epithelial hallmark E-cadherin, and increased the expression of the mesenchymal hallmarks N-cadherin and Vimentin and transcription factors Snail, Slug and Twist; and at the mRNA level, we got the same conclusion through RT-qPCR ( Figure 8B ). MMPs can almost degrade various protein components in ECM, destroy the histological barrier of tumor cell invasion, and play a key role in tumor invasion and metastasis. By RT-qPCR and MMP zymography assay, we found that the mRNA expression of MMP2 and MMP9 was significantly increased in EFEMP2 shRNA-transfected BEAS-2B cells ( Figure 8B ), and their activities were significantly higher in the EFEMP2 shRNA-transfected group than in the negative control group ( Figure 8C ). In summary, EFEMP2 knockdown could promote EMT and enhance the expression and activity of MMP2 and MMP9. Conversely, in EFEMP2 cDNAtransfected lung cancer cells, EFEMP2 up-regulation remarkably increased the expression of E-cadherin and decreased the expression of N-cadherin, Vimentin, Snail, Slug and Twist, at protein ( Figure 9A ) and mRNA levels ( Figure 9B ). In addition, compared with the negative control cells, EFEMP2 cDNA-transfected lung cancer cells had weaker mRNA expression of MMP2 and MMP9 ( Figure 9B ), and their activities were significantly inhibited by EFEMP2 up-regulation ( Figure 9C ). Therefore, EFEMP2 overexpression could hamper the process of EMT and weaken the expression and activity of MMP2 and MMP9 in lung cancer.
Discussion
In our study, we initially detected that the expression of EFEMP2 was down-regulated in lung cancer tissues and cell lines, its low expression was significantly correlated with late clinical stage, low histological grade, positive lymph node metastasis and poor prognosis of NSCLC patients. The effects of EFEMP2 up-or down-regulation on cell proliferation, invasion and metastasis were explored in vitro and in vivo. The results revealed that EFEMP2 played an inhibitory role in the development of lung cancer. EFEMP2 could hamper the process of EMT and reduce the activity of MMPs, and decelerate the proliferation and invasion capacity of lung cancer cells.
The IHC results of lung tissues showed that the high expression rate of EFEMP2 in normal lung tissues was higher than that in lung cancer tissues, and EFEMP2 was highly expressed in well-differentiated carcinoma in contrast with poorly differentiated carcinoma. The high expression of EFEMP2 was negatively associated with poor clinical pathological characteristics and prognosis of lung cancer. We got the same conclusion from the Public database analysis (Oncomine and Kaplan-Meier plotter). On this basis, the expression of EFEMP2 in normal lung epithelial cell line and 4 lung cancer cell lines was further studied by RT-qPCR,Western blotting and ICC. The results showed that the expression of EFEMP2 in 4 lung cancer cell lines was significantly lower than that in normal lung epithelial cell line, which was consistent with the IHC results of lung tissues. So far, the function of EFEMP2 in tumorigenesis had not been fully elucidated, which was complicated and sometimes contradicting, because it displayed both pro-and antineoplastic effects depending on different tumor microenvironment. In 1999, EFEMP2 was first identified as a partner of mutant p53 interaction, also called MBP1 (Mutant p53-Binding Protein 1), and was considered as a candidate oncogene. 5 Since then, with regard to the role of EFEMP2 in tumorigenesis, there have been some contradictory conclusions in the study of various tumors. Gallagher et al by fluorescence in situ hybridisation analysis, found that EFEMP2 gene was located on chromosome 11q13, which was prone to translocation and rearrangement during tumorigenesis, therefore, it was believed that EFEMP2 played an important role in the development of human cancer. Then they further found that in human colon tumor, the mRNA expression of EFEMP2 in tumors was about 2-7 times higher than that in adjacent normal tissues, which suggested that EFEMP2 gene was associated with human colon tumourigenesis. 10 In the same pattern, in colorectal cancer, EFEMP2 was 
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highly expressed even at the early stage, and was identified as a serum biomarker for the early detection of colorectal cancer. 25 Increased EFEMP2 expression was also found in human osteosarcoma clinical specimens and cell lines, and EFEMP2 promoted osteosarcoma cell proliferation and invasion and played critical neoplastic roles in tumor development. 19, 26 In gliomas, EFEMP2 had the carcinogenic potential and its knockdown inhibited the growth and metastasis of cancer cells, high expression of EFEMP2 was related to the poor prognosis of glioblastoma. 18, 27 EFEMP2 expression was up-regulated in cervical carcinoma and ovarian cancer, and its overexpression was significantly associated with the patient's adverse clinical and pathological characteristics and poor prognosis. 16, 17 However, there were some opposite conclusions in the study of other tumors. EFEMP2 was weakly expressed in prostate carcinoma cell lines compared to normal epithelial cells. 28 In human endometrial carcinoma, EFEMP2 expression was significantly decreased in cancer tissues and cell lines, which was negatively correlated with malignant phenotype and poor prognosis. 20 The loss of EFEMP2 expression was also found in breast cancer and associated with grade histology, which suggested that EFEMP2 could be considered as a potential prognostic biomarker. 29 In human bladder cancer, the expression of EFEMP2 was significantly down-regulated in cancer samples and cells, which was negatively correlated with advanced tumor stage, high tumor grade and poor prognosis, and the low expression of EFEMP2 was considered to be a high-risk index of the patient's survival. 30 Our study showed that the role of EFEMP2 in lung cancer was anti-tumor, and EFEMP2 acted as a tumor suppressor gene that inhibited the progress of lung cancer. Whether the high or low expression of EFEMP2 can promote tumorigenesis depends on the type of cancer, and the complexity might originate from the specific microenvironment of each human cancer. 31 Epithelial-mesenchymal transition (EMT) refers to the biological process of the epithelial cell being transformed into a cell with a mesenchymal phenotype by a specific procedure. It is mainly characterized by the reduction of the expression of cell adhesion molecules (such as E-cadherin), the transformation of cytokeratin cytoskeleton into the cytoskeleton dominated by vimentin, and the characteristics of the mesenchymal cells in the form. EMT is an important biological process, during which malignant epithelial cells acquired the migration and invasion capacity, so it is very important for the development of many epithelial cancers. There were also contradictory conclusions about the role of EFEMP2 in the process of EMT. In human osteosarcoma, EFEMP2 knockdown could suppress the invasion and metastasis of osteosarcoma cells by inhibiting EMT, meanwhile EFEMP2 up-regulation could enhance the invasion and metastasis of osteosarcoma cells by inducing EMT, which suggested that EFEMP2 promoted the process of EMT in osteosarcoma cells. 19 On the contrary, in human bladder cancer and endometrial carcinoma, EFEMP2 played inhibitory roles in the process of EMT. EFEMP2 overexpression could inhibit the proliferation, invasion and metastasis of bladder cancer cells and EMT process, while EFEMP2 downregulation could promote the proliferation, invasion and metastasis of bladder cancer cells and EMT process. 30 In the same pattern, EFEMP2 significantly inhibited the proliferation, invasion and metastasis of endometrial carcinoma cells and EMT, therefore, EFEMP2 had the ability to suppress endometrial cancer progression. 20 In our study,
by Western blotting and RT-qPCR, we got the same conclusion that EFEMP2 down-regulation significantly decreased the expression of the epithelial hallmark E-cadherin, and increased the expression of the mesenchymal hallmarks N-cadherin and Vimentin and transcription factors Snail, Slug and Twist; reversely, EFEMP2 upregulation remarkably increased the expression of E-cadherin and decreased the expression of N-cadherin, Vimentin, Snail, Slug and Twist. According to different tumor microenvironments, EFEMP2 played a dual role of inhibition or promotion in the process of EMT. At present, the research on the function of EFEMP2 in tumorigenesis is still in the initial stage, and there are few related literatures. We believe that the focus of future research should be on the upstream and downstream signal pathways of EFEMP2 in cancer progression, as well as the characterization of their intracellular and extracellular partners. Malignant cells have highly invasive ability to invade adjacent areas and metastasize to distant organs by degrading ECM components. Matrix metalloproteinases, including MMP-2 and MMP-9, play a critical role in local invasion, metastasis and angiogenesis. 32 In glioma, the silence of EFEMP2 expression in two glioma cell lines remarkably inhibited cell proliferation, induced cell apoptosis and significantly inhibited the invasive ability of both glioma cells, accompanied by the down-regulation of MMP-2 and MMP-9, which suggested that EFEMP2 could promote the invasion of glioma cells by regulating MMP-2 and MMP-9. Our data indicated that EFEMP2 overexpression notably inhibited the invasion of lung cancer cells and decreased the expression and activity of MMP2 and MMP9, while EFEMP2 knockdown remarkably promoted the invasion of lung normal epithelial cells and enhanced the expression and activity of MMP2 and MMP9. In summary, EFEMP2 could inhibit the invasion of lung cancer cells by weakening the expression and activity of MMP2 and MMP9. It is noteworthy that other fibulin members can also act as modulators of MMPs. EFEMP1 and EFEMP2 have very high homology in structure, and they also have many similar features in the progression of cancer. 13, 14 As in the case of EFEMP2, EFEMP1 played inhibitory roles in lung cancer cell invasion by hampering the process of EMT and downregulating cellular MMP-7, MMP-2 and MMP9. [33] [34] [35] [36] However, in human gliomas, EFEMP1 was significantly up-regulated and promoted tumor cell motility and invasion with elevated expression and activity of matrix metalloproteases, such as MMP-2, MMP-9, ADAMTS-5 and ADAM17. [37] [38] [39] In conclusion, there are reports for prooncogenic and anti-oncogenic roles for EFEMP2, and more in-depth research is needed in the future.
Conclusion
Our study revealed that down-regulated EFEMP2 expression was associated with the malignant phenotype and poor prognosis of lung cancer, which was consistent with the public database analyses. Moreover, EFEMP2 was able to suppress the proliferation, invasion, and metastasis of lung cancer cells in vitro and in vivo by inhibiting EMT and downregulating MMP-2 and MMP9. The study of the mechanism of EFEMP2 in the invasion and metastasis of lung cancer is of great significance in finding new therapeutic strategies to improve the prognosis of lung cancer patients. 
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